MARKET

TPST

TPST

Tempest Therapeutics Inc
NASDAQ
1.690
0.00
0.00%
Opening 13:00 11/25 EST
OPEN
--
PREV CLOSE
1.690
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
10.20
52 WEEK LOW
1.450
MARKET CAP
17.77M
P/E (TTM)
-0.4502
1D
5D
1M
3M
1Y
5Y
Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent With Clinical Benefit Observed In Patients With Cancer
Benzinga · 11/10 14:05
BRIEF-Tempest Reports Q3 Financial Results, Provides Business Update
Reuters · 11/08 13:56
Tempest Therapeutics Q3 EPS $(0.66) Up From $(1.21) YoY
Benzinga · 11/08 13:14
Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit
Dara Burdette, Ph.D., Tempest Senior Director of Discovery Research, to Chair “New Approaches to Solid Tumor Targeting” SessionNicholas DeVito, M.D, Duke University School of Medicine, to present TPST-1495 preclinical data SOUTH SAN FRANCISCO, Calif., Oct....
GlobeNewswire · 10/06 12:00
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022
Upgrades
Benzinga · 09/15 14:16
Ladenburg Thalmann Initiates Coverage On Tempest Therapeutics with Buy Rating, Announces Price Target of $8
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Buy rating and announces Price Target of $8.
Benzinga · 09/15 12:40
--Ladenburg Thalmann Starts Tempest Therapeutics at Buy With $8 Price Target
--Ladenburg Thalmann Starts Tempest Therapeutics at Buy With $8 Price Target
MT Newswires · 09/15 09:03
5 Value Stocks In The Healthcare Sector
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Benzinga · 08/22 14:46
More
About TPST
Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs include TPST-1495 and TPST-1120. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor. TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). TPST-1495, is a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is in a Phase I monotherapy and combination trial in solid tumors.

Webull offers kinds of Tempest Therapeutics Inc stock information, including NASDAQ:TPST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPST stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TPST stock methods without spending real money on the virtual paper trading platform.